Chronic Hypertension: Diagnosis and Management

Correct Answer: Lisinopril

### TLDR The patient presents with poorly controlled hypertension, symptoms suggestive of heart failure, and elevated creatinine indicating chronic kidney disease. **Lisinopril**, an ACE inhibitor, is the most appropriate next therapy as it simultaneously addresses blood pressure control, heart failure, and provides crucial renoprotection. ### Comparison Table | Option | Mechanism | Clinical Nuance | Key Distinction | | :------- | :-------- | :-------------- | :---------------- | | Spironolactone | Aldosterone antagonist; K-sparing diuretic. | For resistant HTN, HFrEF; hyperkalemia risk. | Higher risk of hyperkalemia with elevated creatinine. | | Furosemide | Loop diuretic; increases Na/Cl excretion. | Potent fluid removal for acute/severe congestion. | Primarily for symptom relief, not first-line for BP/CKD. | | Bisoprolol | Beta-1 selective adrenergic blocker. | Reduces HR/contractility; used in HTN, HFrEF. | ACEIs offer more comprehensive organ protection here. | | **Lisinopril** | ACE inhibitor; reduces ATII, increases bradykinin. | First-line for HTN with HF and/or CKD. | Addresses HTN, HF, and renoprotective in CKD. | ### Detailed Breakdown This 66-year-old man presents with a constellation of issues: severely uncontrolled hypertension (188/96 mmHg), symptoms and signs of fluid overload consistent with heart failure (exertional dyspnea, basal crepitations, pitting edema), and evidence of chronic kidney disease (elevated creatinine of 133 µmol/L). He is already on two antihypertensive agents, amlodipine (a calcium channel blocker) and indapamide (a thiazide-like diuretic). The most appropriate next therapy is **Lisinopril** due to its multifaceted benefits in this clinical scenario: 1. **Antihypertensive Efficacy:** As an ACE inhibitor, lisinopril is highly effective at lowering blood pressure, which is crucial given his current reading. 2. **Heart Failure Management:** ACE inhibitors are foundational therapy for heart failure, reducing both preload and afterload, improving cardiac remodeling, and reducing morbidity and mortality. His symptoms and physical exam findings strongly suggest heart failure. 3. **Renoprotection:** Perhaps most importantly in this patient with elevated creatinine, ACE inhibitors are renoprotective. They reduce intraglomerular pressure and proteinuria, thereby slowing the progression of chronic kidney disease, particularly in patients with hypertensive nephropathy. Regular monitoring of serum creatinine and potassium is necessary after initiation. Let's consider why the other options are less optimal: * **Spironolactone** is an aldosterone antagonist that can be beneficial in resistant hypertension and heart failure with reduced ejection fraction (HFrEF). However, given the patient's elevated creatinine, adding spironolactone carries a significant risk of hyperkalemia, especially when combined with an ACE inhibitor. While it might be considered later, initiating an ACEI is generally preferred first in this context. * **Furosemide** is a potent loop diuretic used primarily for acute symptom relief of severe fluid overload. While the patient has signs of fluid retention, he is already on a diuretic (indapamide). Furosemide does not offer the same long-term cardiovascular and renal protective benefits as an ACE inhibitor, nor is it ideal as a primary agent for chronic blood pressure control in this setting. * **Bisoprolol** (a beta-blocker) is indicated for hypertension and heart failure. However, ACE inhibitors typically offer more direct benefits for renal protection and are often preferred as a third agent for severe hypertension with concurrent kidney disease and heart failure symptoms. Initiating an ACEI first addresses a broader range of the patient's problems comprehensively.